Market Overview

Spherix, Fullife Healthcare Sign Supply, License Pact for D-Tagatose

Related SPEX
Spherix Prices 5.719M Units; 1.23 Shares Of Common At Exercise Price Of $0.43
Spherix Offers Update on NNTP v. Huawei Case: Markman Hearing Remains Scheduled for Jul. 17, Trial Set Feb. 8, '16

Spherix Incorporated (Nasdaq: SPEX) and Fullife Healthcare Pvt. Ltd. – an innovation-driven company focused on bringing unique healthcare solutions to India – today announced the signing of a supply and license agreement for the use of D-tagatose in nutraceutical products in India.

Under the terms of the agreement, Spherix has granted Fullife an exclusive, royalty-bearing license in India for use of Spherix's clinical data and proprietary know-how to support marketing and dosing of the D-tagatose that Spherix will also be supplying. The D-tagatose will be used in food or cosmetic products that may provide health benefits in return for a fixed royalty on gross sales. Spherix will provide bulk D-Tagatose to Fullife and Fullife will be responsible for all testing and development of products containing D-Tagatose for sale in India. Financial terms of the agreement were not disclosed.

Posted-In: News


Related Articles (SPEX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters